Clinical trials: Antipsychotic Agents
Schizophrenia, Schizoaffective Disorder
PROFILe3: Epidemiologic Survey in Patients With Schizophrenia or Schizoaffective Disorders
The purpose of this study is to evaluate epidemiological characteristics of patients that experience relapse and need an admission in psychiatric acute units across Spain.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT00399334
- Testing
- antipsychotic medications
- Volunteers
- 1,607 people
- Sponsor
- Janssen-Cilag, S.A.
Schizophrenia, Psychotic Disorders
A Study of Risperidone in Combination With Lorazepam Compared With Standard Therapy for Emergency Treatment of Schizophrenic Patients
The purpose of the study is to show that risperidone (an antipsychotic medication) combined with lorazepam (an anti-anxiety medication) is more effective than conventional therapy administered by intramuscular injection for…
- Conditions
- Schizophrenia, Psychotic Disorders, Emergency Treatment
- Trial name
- NCT00249171
- Testing
- risperidone
- Volunteers
- 226 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
SSRI-Refractory Obsessive-Compulsive Disorder
Effectiveness and Safety of Atypical Antipsychotic Agents in Augmenting SSRI-Refractory Obsessive-Compulsive Disorder
Objective: Although atypical antipsychotic drugs (AAPDs) have been found effective in the augmentation of serotonin reuptake inhibitors (SRIs) for treatment-resistant obsessive-compulsive disorder (OCD) in short terms trials…
- Trial name
- OCDDRUG (NCT00854919)
- Testing
- atypical antipsychotic drug, exposure response prevention
- Where
- Japan
- Sponsor
- Osaka City University
Schizophrenia, Psychotic Disorders
Study To Assess Differential Sensitivity Of 2 Spatial Working Memory Tests In Schizophrenics Treated With Risperidone
To assess the effect of risperidone 2 mg daily (QD) on the differential sensitivity of 2 spatial working memory tests (the GMLT and MDR) in non-agitated, drug-naive patients suffering from first-episode…
- Trial name
- NCT00174200
- Testing
- Risperidone 2 mg
- Where
- 3 sites in Canada, Russia
- Volunteers
- 20 people
- Sponsor
- Pfizer
Schizophrenia
Comparison of Optimal Antipsychotic Treatments for Adults With Schizophrenia
This study will compare the safety and effectiveness of three different antipsychotic medications, as well as the use of other medications to limit treatment side effects, in adults with schizophrenia.
- Trial name
- COATS (NCT00802100)
- Testing
- Olanzapine, Perphenazine, Aripiprazole
- Where
- 13 sites in United States
- Volunteers
- 21 people
- Sponsor
- National Institute of Mental Health (NIMH)
Schizophrenia
A Study of the Effect of Food and Posture on the Pharmacokinetics of a Single Dose of ER OROS Paliperidone
The purposes of this study are to evaluate the effect of food on the pharmacokinetics of extended-release (ER) OROS paliperidone in healthy men, and to evaluate the effect of posture on the pharmacokinetics of ER OROS…
- Trial name
- NCT00838669
- Testing
- Extended release OROS paliperidone
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
HIV Infections
Interaction Between Fosamprenavir/Ritonavir and a Single-dose Olanzapine (FORZA)
The effect of fosamprenavir/ritonavir (steady state) on the pharmacokinetics of a single dose of olanzapine will be studied. In this study, the investigators expect an inducible effect of fosamprenavir/ritonavir on the CYP1A2 and…
- Trial name
- FORZA (NCT00977301)
- Testing
- fosamprenavir/ritonavir, olanzapine
- Where
- Netherlands
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
First Episose Psychosis, Metabolic Disease
The ATP Project (Antipsychotic-TEP-Psychosis)
The goal of this observational study is to the early impacts of psychosis and antipsychotic medications on brain metabolism in young adults recently diagnosed with a first episode of psychosis.
- Conditions
- First Episose Psychosis, Metabolic Disease, Psychosis; Episode
- Trial name
- ATP (NCT06651112)
- Testing
- Antipsychotic drugs
- Where
- Canada
- Volunteers
- 18 people
- Sponsor
- Université de Sherbrooke
Volunteers on Chronic, Stable Antipsychotic Regimens
Staccato Loxapine Multidose PK
The objectives of this trial are to assess the safety, tolerability, and pharmacokinetics of multiple inhaled doses of Staccato Loxapine.
- Trial name
- NCT00555412
- Testing
- A - 10 mg loxapine q 4 h x 3 (30 mg total), B - 10 mg x 1, 5 mg x 2 loxapine q 4 h (20 mg total), C - 5 mg loxapine q 4 h x 3 (15 mg total)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Alexza Pharmaceuticals, Inc.
Healthy, Pharmacokinetics of Quetiapine
Study to Evaluate the Effect of Multiple-dose of Fluvoxamine on the Plasma Concentration of Quetiapine (FK949E) in Healthy Male Volunteers
The objective of the study was to assess the effect of multiple-dose fluvoxamine on the pharmacokinetics of quetiapine (FK949E) in healthy adult male subjects. The safety of FK949E in the population was also evaluated.
- Trial name
- NCT01908296
- Testing
- FK949E, fluvoxamine
- Where
- Japan
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Child Mental Disorders, Obesity
Healthy Bodies, Healthy Kids
The US prevalence of childhood-onset obesity and type 2 diabetes, both predictors of cardiovascular risk, have increased to epidemic proportions in recent decades.
- Conditions
- Child Mental Disorders, Obesity, Metabolic Syndrome
- Trial name
- NCT01222494
- Testing
- Behavioral Weight Loss, Diet and Exercise Education
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Schizophrenia
Treatment of Patients With Recently Exacerbated Schizophrenia With Paliperidone Palmitate
The purpose of this study is to explore the efficacy of paliperidone palmitate administered as a once monthly injection in patients with an acute exacerbation of schizophrenia.
- Trial name
- NCT01448720
- Testing
- Paliperidone palmitate
- Where
- 12 sites in Brazil, Colombia and 1 more
- Volunteers
- 142 people
- Sponsor
- Janssen-Cilag Farmaceutica Ltda.
Schizophrenia
Alleviating the Metabolic Side Effects of Antipsychotic Medications
The use of antipsychotic medications has increased over the past decade. While more recently developed medications are improved with regards to extrapyramidal side effects, the use of atypical antipsychotics has been associated…
- Trial name
- NCT01567124
- Testing
- Moxonidine
- Where
- 4 sites in Australia
- Sponsor
- Baker Heart and Diabetes Institute
Schizophrenia
Predicting Antipsychotic Discontinuation in Psychosis
The purpose of this study is to determine whether dopamine synthesis capacity by using [18 fluorine(F)]-DOPA PET for patients with schizophrenia in the maintenance phase can predict treatment discontinuation.
- Trial name
- PADP (NCT02884518)
- Testing
- PET, clinical scale
- Where
- South Korea
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Glioblastoma Multiforme, MGMT-Unmethylated Glioblastoma
Repurposing Chlorpromazine in the Treatment of Glioblastoma
This study evaluates the addition of chlorpromazine to the first-line therapeutic protocol, i.e. maximal well-tolerated surgical resection followed by radiotherapy plus concomitant and adjuvant chemotherapy with temozolomide, in…
- Trial name
- RACTAC (NCT04224441)
- Testing
- Chlorpromazine Pill
- Where
- 3 sites in Italy
- Volunteers
- 41 people
- Sponsor
- Marco G Paggi, MD, PhD
Adverse Effect of Other Antipsychotics and Neuroleptics
Adverse Events and Genomics in Schizophrenia
The purpose of this study is to find genes that predict whether or not a person will develop side effects to antipsychotic medications, such as weight gain, blood sugar dysregulation, or immune cell abnormalities.
- Trial name
- AEGIS (NCT01966588)
- Testing
- Blood samples for whole genomic/transcriptomic sequencing, UKU Side Effect Rating Scale
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- University of British Columbia
Schizophrenia
Pan European Collaboration on Antipsychotic Naive Schizophrenia (PECANS)
The investigators want to relate disturbances in first-episode schizophrenic patients in (dopaminergic) D2 receptors, brain structure, brain function, and information processing to each other and to psychopathology.
- Trial name
- PECANS (NCT01154829)
- Testing
- amisulpride, aripiprazole
- Where
- Denmark
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Schizophrenia, Schizoaffective Disorder
Schizophrenia, Antipsychotic Treatment and the Risk for Diabetes Mellitus
This preliminary study aims to investigate the mechanism of higher rates of type 2 diabetes mellitus in patients with schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Delusional Disorder
- Trial name
- NCT00222807
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Schizophrenia
A Study to Evaluate the Effectiveness and Safety of 3 Doses of Paliperidone Palmitate in Treating Subjects With Schizophrenia
The purpose of this study is to evaluate the effectiveness and safety of 3 doses of paliperidone palmitate in treating subjects with schizophrenia.
- Trial name
- NCT00210548
- Testing
- paliperidone palmitate
- Volunteers
- 366 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia With Impulsivity
Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Schizophrenia With Impulsivity
The purpose of this study is to evaluate the effect of brexpiprazole, via functional magnetic resonance imaging (fMRI), on the right ventrolateral prefrontal cortex (VLPFC) activated by impulsive behavior.
- Trial name
- NCT02194933
- Testing
- Brexpiprazole
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.